ZA200706294B - Roflumilast for the treatment of diabetes mellitus - Google Patents

Roflumilast for the treatment of diabetes mellitus

Info

Publication number
ZA200706294B
ZA200706294B ZA200706294A ZA200706294A ZA200706294B ZA 200706294 B ZA200706294 B ZA 200706294B ZA 200706294 A ZA200706294 A ZA 200706294A ZA 200706294 A ZA200706294 A ZA 200706294A ZA 200706294 B ZA200706294 B ZA 200706294B
Authority
ZA
South Africa
Prior art keywords
roflumilast
treatment
diabetes mellitus
mellitus
diabetes
Prior art date
Application number
ZA200706294A
Other languages
English (en)
Inventor
Kley Hans-Peter
Hauser Daniela
Bredenbroeker Dirk
Kemkowski Joerg
Hanauer Guido
Schmidt Beate
Wurst Wilhelm
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of ZA200706294B publication Critical patent/ZA200706294B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
ZA200706294A 2005-03-08 2007-07-27 Roflumilast for the treatment of diabetes mellitus ZA200706294B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101772 2005-03-08

Publications (1)

Publication Number Publication Date
ZA200706294B true ZA200706294B (en) 2008-09-25

Family

ID=34938922

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706294A ZA200706294B (en) 2005-03-08 2007-07-27 Roflumilast for the treatment of diabetes mellitus

Country Status (15)

Country Link
US (2) US8017633B2 (https=)
EP (1) EP1874308A1 (https=)
JP (2) JP5091106B2 (https=)
KR (1) KR101302838B1 (https=)
CN (2) CN102600144A (https=)
AU (1) AU2006222060B2 (https=)
BR (1) BRPI0609371A2 (https=)
CA (1) CA2599376C (https=)
EA (1) EA015382B1 (https=)
IL (2) IL185277A (https=)
MX (1) MX2007010560A (https=)
NO (1) NO20074943L (https=)
NZ (1) NZ560269A (https=)
WO (1) WO2006094933A1 (https=)
ZA (1) ZA200706294B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3993169B2 (ja) 2002-02-11 2007-10-17 アンタレス・ファーマ・インコーポレーテッド 皮内注射器
JP5216328B2 (ja) 2005-01-24 2013-06-19 アンタレス ファーマ インコーポレイテッド あらかじめ充填された針補助シリンジジェット式注射器
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2007131013A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Two-stage reconstituting injector
JP2010502670A (ja) * 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
EP2268342B1 (en) 2008-03-10 2015-09-16 Antares Pharma, Inc. Injector safety device
CN101548972B (zh) * 2008-04-03 2012-10-17 万特制药(海南)有限公司 一种含有瑞格列奈的固体药物组合物
EP3581224A1 (en) 2008-08-05 2019-12-18 Antares Pharma, Inc. Multiple dosage injector
CN102612381B (zh) 2009-03-20 2015-09-09 安塔瑞斯制药公司 危险试剂注入系统
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
WO2013134244A2 (en) 2012-03-06 2013-09-12 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
ES2969984T3 (es) 2013-02-11 2024-05-23 Antares Pharma Inc Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
JP6030803B2 (ja) 2013-03-11 2016-11-24 アンタレス・ファーマ・インコーポレーテッド ピニオンシステムを有する用量注射器
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
EP3165224A1 (en) * 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB202306663D0 (en) * 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
CZ14795A3 (en) 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
EP0671936A1 (en) 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
KR970705562A (ko) 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
UA48216C2 (uk) 1996-01-31 2002-08-15 Бік Гулден Ломберг Кеміше Фабрік Гмбх Фенантридини та лікарський засіб для лікування захворювань дихальних шляхів
DE19617864A1 (de) 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE59811840D1 (de) 1997-09-12 2004-09-23 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
ATE294793T1 (de) 1999-01-15 2005-05-15 Altana Pharma Ag Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
EP1650193A3 (en) 1999-01-15 2006-10-04 ALTANA Pharma AG 6-Phenylphenanthridines with PDE-IV inhibiting activity
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
WO2001035979A2 (en) 1999-11-13 2001-05-25 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
US6642250B2 (en) 1999-12-08 2003-11-04 Grelan Pharmaceutical Co., Ltd. 1,8-naphthyridin-2(1H)-one derivatives
AU2001250820A1 (en) 2000-03-13 2001-09-24 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclohexene derivatives useful as antagonists of the motilin receptor
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
AU2001261962B2 (en) * 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
WO2002013798A2 (en) 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
BR0113167A (pt) 2000-08-11 2003-06-24 Ono Pharmaceutical Co Derivados de piperidina e agente que compreende o derivado como ingrediente ativo
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
ATE305467T1 (de) * 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
WO2002060898A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
EE05386B1 (et) 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
JP2005506286A (ja) * 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリック−ａｍｐ関連疾患の治療を目的としたメラノコルチン受容体アゴニストおよびホスホジエステラーゼ阻害剤の併用投与
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
ME00565A (en) * 2002-05-28 2011-12-20 Topically applicable pharmaceutical preparation
AU2003253130A1 (en) 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004098596A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2004098598A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098595A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098597A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
EA012279B1 (ru) * 2003-05-22 2009-08-28 Никомед Гмбх Композиция, включающая ингибитор pde4 и ингибитор pde5
WO2005020926A2 (en) * 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
WO2005023253A1 (en) 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
WO2005041864A2 (en) 2003-10-21 2005-05-12 Pharmacia Corporation Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
WO2005116653A2 (en) 2004-04-13 2005-12-08 Arena Pharmaceuticals, Inc. Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus

Also Published As

Publication number Publication date
AU2006222060A1 (en) 2006-09-14
JP2012188448A (ja) 2012-10-04
CN101137368A (zh) 2008-03-05
JP5611275B2 (ja) 2014-10-22
US8017633B2 (en) 2011-09-13
NZ560269A (en) 2010-12-24
BRPI0609371A2 (pt) 2010-03-30
CA2599376C (en) 2014-05-13
CA2599376A1 (en) 2006-09-14
US20080214625A1 (en) 2008-09-04
US8541456B2 (en) 2013-09-24
AU2006222060B2 (en) 2011-09-01
KR20070111539A (ko) 2007-11-21
NO20074943L (no) 2007-10-01
US20110269750A1 (en) 2011-11-03
CN101137368B (zh) 2012-05-16
JP2008532974A (ja) 2008-08-21
MX2007010560A (es) 2008-02-21
IL185277A0 (en) 2008-02-09
HK1116077A1 (en) 2008-12-19
IL221006A0 (en) 2012-08-30
EP1874308A1 (en) 2008-01-09
EA015382B1 (ru) 2011-08-30
EA200701845A1 (ru) 2008-02-28
IL185277A (en) 2013-08-29
JP5091106B2 (ja) 2012-12-05
KR101302838B1 (ko) 2013-09-03
WO2006094933A1 (en) 2006-09-14
CN102600144A (zh) 2012-07-25

Similar Documents

Publication Publication Date Title
ZA200706294B (en) Roflumilast for the treatment of diabetes mellitus
ZA200900501B (en) Combination treatment for diabetes mellitus
IL189212A0 (en) Therapeutic agent for diabetes
EP2787345B8 (en) Treatment options for fabry disease
IL192369A0 (en) Therapeutic agent for diabetes
HUS1600047I1 (hu) Eljárások hipoglikémiás szerek beadására
IL185761A0 (en) Pharmaceutical compositions for treating diabetes
GB0509326D0 (en) Therapeutic compounds
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
GB0509405D0 (en) Therapeutic compounds
GB0513747D0 (en) Therapeutic compounds
IL189928A0 (en) Thiophene derivatives for the treatment of diabetes
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
GB0516068D0 (en) Well treatment
GB0525540D0 (en) New treatment
GB0511769D0 (en) Treatment
GB0502171D0 (en) Well treatment
GB0423173D0 (en) Treatment of diabetes
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
HU0400847D0 (en) Pharmaceutical composition for the treatment of diabetes
ZA200806143B (en) Therapeutic agent for diabetes
HK1118290A (en) Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
GB0515580D0 (en) Therapeutic compounds
HK1118018A (en) Therapeutic agent for diabetes
HK1111613A (en) Compounds for flaviviridae treatment